Very positive moves with the Jansenn and GSK deals. Multiple paths to all oral and non-exclusive too. Saves a lot of money on hep c which is getting increasingly competitive while they will own CF for years.
just share costs. no upfront or milestones. so they retain a lot of the sales if marketed. doubt this will pop the stock much. just helps their cash burn rate. yawn. let's see what mr market says at 930am. notice it was the day of earnings. maybe that's why the delay till today. maybe clinical news after the belll today??? earnings good or bad due to these announcements? hmmmmm
Long VRTX for many years now. VRTX has missed on earnings the last two quarters and I suspect they will miss again. This is managements way of masking poor earnings for now but long term the stock is a hold and should be bought on dips.